These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15678115)

  • 1. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor.
    Ding G; Jiang Q; Zhang L; Zhang ZG; Li L; Knight RA; Ewing JR; Wang Y; Chopp M
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):87-97. PubMed ID: 15678115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
    Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
    Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
    Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
    Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy.
    Shuaib A; Yang Y; Nakada MT; Li Q; Yang T
    J Cereb Blood Flow Metab; 2002 Feb; 22(2):215-22. PubMed ID: 11823719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI of combination treatment of embolic stroke in rat with rtPA and atorvastatin.
    Ding G; Jiang Q; Li L; Zhang L; Zhang ZG; Panda S; Ewing JR; Chopp M
    J Neurol Sci; 2006 Jul; 246(1-2):139-47. PubMed ID: 16626754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiographic evaluation of middle cerebral artery reperfusion caused by platelet glycoprotein IIb/IIIa receptor complex antagonist murine 7E3 F(ab')2 in a model of focal cerebral ischemia in rats.
    Yang Y; Li Q; Nakada MT; Yang T; Shuaib A
    J Neurosurg; 2001 Apr; 94(4):582-8. PubMed ID: 11302656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Map-ISODATA demarcates regional response to combination rt-PA and 7E3 F(ab')2 treatment of embolic stroke in the rat.
    Li L; Jiang Q; Ding G; Zhang L; Zhang ZG; Ewing JR; Knight RA; Kapke A; Soltanian-Zadeh H; Chopp M
    J Magn Reson Imaging; 2005 Jun; 21(6):726-34. PubMed ID: 15906325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke.
    Desilles JP; Loyau S; Syvannarath V; Gonzalez-Valcarcel J; Cantier M; Louedec L; Lapergue B; Amarenco P; Ajzenberg N; Jandrot-Perrus M; Michel JB; Ho-Tin-Noe B; Mazighi M
    Stroke; 2015 Nov; 46(11):3241-8. PubMed ID: 26443832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion.
    Zhang ZG; Zhang L; Tsang W; Goussev A; Powers C; Ho KL; Morris D; Smyth SS; Coller BS; Chopp M
    Brain Res; 2001 Sep; 912(2):181-94. PubMed ID: 11532435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat.
    Jiang Q; Zhang RL; Zhang ZG; Ewing JR; Divine GW; Chopp M
    J Cereb Blood Flow Metab; 1998 Jul; 18(7):758-67. PubMed ID: 9663506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
    Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
    Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
    Zhang L; Zhang ZG; Zhang RL; Lu M; Krams M; Chopp M
    Stroke; 2003 Jul; 34(7):1790-5. PubMed ID: 12805500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.
    Choudhri TF; Hoh BL; Zerwes HG; Prestigiacomo CJ; Kim SC; Connolly ES; Kottirsch G; Pinsky DJ
    J Clin Invest; 1998 Oct; 102(7):1301-10. PubMed ID: 9769322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
    Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
    Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
    Zhang L; Zhang ZG; Ding GL; Jiang Q; Liu X; Meng H; Hozeska A; Zhang C; Li L; Morris D; Zhang RL; Lu M; Chopp M
    Circulation; 2005 Nov; 112(22):3486-94. PubMed ID: 16316970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.
    Molina CA; Ribo M; Rubiera M; Montaner J; Santamarina E; Delgado-Mederos R; Arenillas JF; Huertas R; Purroy F; Delgado P; Alvarez-Sabín J
    Stroke; 2006 Feb; 37(2):425-9. PubMed ID: 16373632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
    Lapchak PA; Araujo DM; Song D; Zivin JA
    Stroke; 2002 Jan; 33(1):147-52. PubMed ID: 11779904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
    Allahtavakoli M; Amin F; Esmaeeli-Nadimi A; Shamsizadeh A; Kazemi-Arababadi M; Kennedy D
    Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):335-9. PubMed ID: 25899606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.